Eureka Therapeutics
Eureka Therapeutics is a US-based cell therapy company that leads 2 cancer trials in OnCo, testing the ARTEMIS T-cell therapies ECT204 and ET140203 in hepatoblastoma and hepatocellular carcinoma.
Overview
Eureka Therapeutics is a clinical-stage biopharmaceutical company developing T-cell therapies for solid tumours using its E-ALPHA antibody discovery and ARTEMIS T-cell receptor platforms. Its clinical programmes are ECT204 for GPC3-positive adult liver cancer and ET140203 for AFP-positive paediatric liver cancer. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT04634357 (phase 1/2, ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular...) and NCT04864054 (phase 1/2, GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.